A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2 - Concepedia

Concepedia

Publication | Open Access

A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

DOI Full Paper Access

34

Citations

44

References

2013

Year

Beata Holkova, Jeffrey G. Supko, Matthew M. Ames, Joel M. Reid, Geoffrey I. Shapiro, Edward Brent Perkins, Viswanathan Ramakrishnan, Mary Beth Tombes, Connie Honeycutt, Renee M. McGovern,

Clinical Cancer Research

Abstract

Alvocidib combined with vorinostat is well tolerated. Although disease stabilization occurred in some heavily pretreated patients, objective responses were not obtained with these schedules.

References

	Year	Citations

Page 1